{"id":691133,"date":"2024-03-12T08:40:02","date_gmt":"2024-03-12T08:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=691133"},"modified":"2024-03-12T08:40:02","modified_gmt":"2024-03-12T08:40:02","slug":"chronic-neuropathic-pain-market-to-witness-growth-by-2032-estimates-delveinsight-wex-pharma-lexicon-pharma-bayer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-neuropathic-pain-market-to-witness-growth-by-2032-estimates-delveinsight-wex-pharma-lexicon-pharma-bayer_691133.html","title":{"rendered":"Chronic Neuropathic Pain Market to Witness Growth by 2032, Estimates DelveInsight | WEX Pharma, Lexicon Pharma, Bayer"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1710179860.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Neuropathic Pain Market to Witness Growth by 2032, Estimates DelveInsight | WEX Pharma, Lexicon Pharma, Bayer\" src=\"https:\/\/www.abnewswire.com\/uploads\/1710179860.jpeg\" alt=\"Chronic Neuropathic Pain Market to Witness Growth by 2032, Estimates DelveInsight | WEX Pharma, Lexicon Pharma, Bayer\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Chronic Neuropathic Pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Neuropathic Pain pipeline products will significantly revolutionize the Chronic Neuropathic Pain market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Chronic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Chronic Neuropathic Pain, historical and forecasted epidemiology as well as the Chronic Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Chronic Neuropathic Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Chronic Neuropathic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-neuropathic-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Chronic Neuropathic Pain Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">According to International Association for the Study of Pain (IASP), Chronic Neuropathic Pain is defined as &ldquo;pain initiated or caused by a primary lesion or dysfunction in the nervous system. Chronic Chronic Neuropathic Pain is common and may be related to an underlying health condition such as cancer or diabetic neuropathy, or it could be related to treatments such as chemotherapy.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Chronic Neuropathic Pain Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Chronic Neuropathic Pain market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)&nbsp;<\/li>\n<li>According to Bouhassira D, the prevalence of Chronic Neuropathic Pain in the general population may be as high as 7 to 8%, accounting for 20 to 25% of individuals with chronic pain&nbsp;<\/li>\n<li>In a study by Pottathil S et.al, the incidence of chronic Chronic Neuropathic Pain is 10&ndash;14% in the United<\/li>\n<li>Kingdom, 9.8&ndash;12.4% in the United States, and 7&ndash;10% worldwide&nbsp;<\/li>\n<li><strong>Key Chronic Neuropathic Pain Companies:<\/strong> WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, and others<\/li>\n<li><strong>Key Chronic Neuropathic Pain Therapies:<\/strong> Halneuron, LX9211, BAY2395840, and others&nbsp;<\/li>\n<li>The Chronic Neuropathic Pain epidemiology based on gender analyzed that Chronic Neuropathic Pain disease affects females more as compared to males&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Get a Free sample for the Chronic Neuropathic Pain Market Report:<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-neuropathic-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/chronic-neuropathic-pain-market<\/a><\/p>\n<p style=\"text-align: justify;\">Key benefits of the Chronic Neuropathic Pain Market report:<\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Chronic Neuropathic Pain market report covers a descriptive overview and comprehensive insight of the Chronic Neuropathic Pain Epidemiology and Chronic Neuropathic Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Chronic Neuropathic Pain market report provides insights on the current and emerging therapies.<\/li>\n<li>Chronic Neuropathic Pain market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Chronic Neuropathic Pain market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Chronic Neuropathic Pain market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Chronic Neuropathic Pain epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-neuropathic-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Chronic Neuropathic Pain Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Chronic Neuropathic Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. &nbsp;<\/p>\n<p style=\"text-align: justify;\"><em>&ldquo;The approval of novel therapies for the treatment of Chronic Neuropathic Pain has led to a major uptick in the DNP drugs market, In January 2022, US FDA approved the Senza Omnia spinal cord stimulation (SCS) system for the treatment of chronic Chronic Neuropathic Pain. Another drug, Tarlige (Mirogabalin besylate), was approved by PMDA Japan for NP, in 2022.&rdquo;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Chronic Neuropathic Pain market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Chronic Neuropathic Pain<\/li>\n<li>Prevalent Cases of Chronic Neuropathic Pain by severity<\/li>\n<li>Gender-specific Prevalence of Chronic Neuropathic Pain<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Chronic Neuropathic Pain<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Neuropathic Pain market or expected to get launched during the study period. The analysis covers Chronic Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Chronic Neuropathic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Chronic Neuropathic Pain treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-neuropathic-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Chronic Neuropathic Pain Medications<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Halneuron:<\/strong> WEX Pharmaceuticals Inc.<\/li>\n<li><strong>LX9211:<\/strong> Lexicon Pharmaceuticals Inc.<\/li>\n<li><strong>BAY2395840:<\/strong> Bayer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The major strength of the Chronic Neuropathic Pain (NP) market is the potential emerging therapies&nbsp;<\/li>\n<li>Growing research and developmental activities about this indication<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Neuropathic Pain Market Unmet Needs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Challenges in diagnoses<\/li>\n<li>Development of novel therapies<\/li>\n<li>Limitations in gene therapy<\/li>\n<li>Poor disease understanding<\/li>\n<li>Clinical biomarkers<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Chronic Neuropathic Pain Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Chronic Neuropathic Pain Companies:<\/strong> WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, and others<\/li>\n<li><strong>Key Chronic Neuropathic Pain Therapies:<\/strong> Halneuron, LX9211, BAY2395840, and others<\/li>\n<li><strong>Chronic Neuropathic Pain Therapeutic Assessment:<\/strong> Chronic Neuropathic Pain current marketed and Chronic Neuropathic Pain emerging therapies<\/li>\n<li><strong>Chronic Neuropathic Pain Market Dynamics:&nbsp;<\/strong>Chronic Neuropathic Pain market drivers and Chronic Neuropathic Pain market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Chronic Neuropathic Pain Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Chronic Neuropathic Pain Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Chronic Neuropathic Pain market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-neuropathic-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Chronic Neuropathic Pain market forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Chronic Neuropathic Pain Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Chronic Neuropathic Pain<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Chronic Neuropathic Pain<\/p>\n<p style=\"text-align: justify;\">4. Chronic Neuropathic Pain Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Chronic Neuropathic Pain Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Chronic Neuropathic Pain Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Chronic Neuropathic Pain Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Chronic Neuropathic Pain&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Chronic Neuropathic Pain Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Chronic Neuropathic Pain Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Chronic Neuropathic Pain Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Chronic Neuropathic Pain Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Chronic Neuropathic Pain Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Chronic Neuropathic Pain Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Chronic Neuropathic Pain Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Chronic Neuropathic Pain Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Chronic Neuropathic Pain Appendix<\/p>\n<p style=\"text-align: justify;\">18. Chronic Neuropathic Pain Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-neuropathic-pain-market-to-witness-growth-by-2032-estimates-delveinsight-wex-pharma-lexicon-pharma-bayer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-neuropathic-pain-market-to-witness-growth-by-2032-estimates-delveinsight-wex-pharma-lexicon-pharma-bayer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Chronic Neuropathic Pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Neuropathic Pain pipeline products will significantly revolutionize the Chronic Neuropathic Pain market dynamics. DelveInsight&rsquo;s &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-neuropathic-pain-market-to-witness-growth-by-2032-estimates-delveinsight-wex-pharma-lexicon-pharma-bayer_691133.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-691133","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/691133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=691133"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/691133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=691133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=691133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=691133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}